Dan

Seasoned executive brings more than three decades of immunotherapy and drug discovery experience PITTSBURGH, May 16, 2025 (GLOBE NEWSWIRE) — BlueSphere Bio, a clinical stage drug development company focused on novel T cell based therapies, today announced the appointment of Alan Korman, Ph.D., as Chief Scientific Officer. Dr. Korman brings extensive immunotherapy drug discovery and

PITTSBURGH, June 25, 2024 (GLOBE NEWSWIRE) — BlueSphere Bio, a drug development company focused on novel T-cell receptor (TCR) based therapies for oncology and non-oncology indications, today announced a collaboration with NMDP BioTherapies℠ (formerly Be The Match BioTherapies), an organization offering solutions for companies developing and commercializing cell and gene therapies, to advance BlueSphere’s first clinical trial evaluating

PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced a strategic collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health. The collaboration will

TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse  First patient to be enrolled in 4Q2024 Nomination of Three additional novel TCR candidates expand HLA population coverage and addressable market size TCX 102 Development Program:Autologous TCR-based cell

PITTSBURGH, PA, March 1, 2023 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present an overview of the Company’s anticipated first in human

PITTSBURGH, PA, February 6, 2023 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor

Dr. Bahceci brings more than two decades of combined clinical and drug development experience PITTSBURGH, PA, January 30, 2023 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the appointment of Erkut Bahceci, M.D.,